Ichiza 'Manini': imiyalelo yokusebenzisa

Ukulungiselela "Mannino" yemiyalezo ichaza iziyobisi antidiabetic yimpumelelo ukuba lobhaliso inn (International Nonproprietary Amagama) gama lithi "Glibenclamide". Le into ungamandla ophambili ekulungiseleleni, apho iveliswa abenzi ngohlobo iipilisi, zalishumi 1,75 mg okanye 3.5 mg. Ukwakheka neziyobisi iikhompawundi abangabancedani nazo ziquka monohydrate lactose, dust, ukutya additive E 124 - cochineal idayi, iitapile starch gimetelloza.

Iimpawu pharmacokinetic beziyobisi ukuba glibenclamide - into ephambili esebenzayo - siqulethwe kwi ekuqulunqweni ngohlobo micronized. Oku kwenza kube lula ukwandisa izinga kwii-ichiza kunye nokwandisa ummandla sokufunxa yayo. Kwakhona, ukufakwa ngempumelelo ngakumbi yeekhomponenti zeziyobisi inegalelo methylhydroxyethylcellulose, eyinxenye ye yokulungiselela "Mannino".

Imiyalelo yokusebenzisa uya kwazisa ukuba additive ukuba phantse nafuthe isimo umzimba, kodwa, nangona kunjalo, yenza kube lula kakhulu kakhulu ukwandisa ixesha yokuhlala amacandelo ichiza kwisigaba abasasazekileyo, eyona obunemveliso ngezenzo zakhe. Ngexesha lesi sigaba uyondelelwano lwee- ichiza kumacandelo plasma kwandisa kathathu ukuya kahlanu, ngaloo ndlela kukho ukwehla omkhulu isixa glucose.

Medicament "Mannino" evelele sikhokelo kuthetha ukuba ipropati wendele ngokukhawuleza ukusuka iphecana zesisu kunye nefomu yayo micronized of glibenclamide amandla kukhululwa ngokupheleleyo ukusuka khompawundi abangabancedani emzimbeni imizuzu emihlanu. Le ndlela yenza kube lula ukuba uthathe ichiza nje phambi kokuba isidlo, kuba 5 - imizuzu-10 ngaphambili. Xi Incopho kwenzeka ukulungiselela ngaphambili, kwaye inyathelo layo, ngoko, oko nokomzimba. Nangona simiso, ulwamkelo ngaxeshanye lokutya akukho tshintsho luza kubakho kwi intshukumo beziyobisi. Ukulungiselela "Mannino" uye kumgangatho we-100% bioavailability. Bawo-ibubomi kumzimba ngumlinganiselo enye enesiqingatha ukuya kwiiyure ezintathu ezinesiqingatha.

Ixesha ezinzileyo isiphumo hypoglycemic of glibenclamide siyagcinwa imini yonke.

Iimpawu pharmacodynamic beziyobisi, "Manini" yemiyalezo ikuchaza ngale ndlela. Medikamet Oku kuphucula secretion kwencindi xa ofunxayo kwi iiseli beta zepancreas, kwaye ichiza yandisa insulin onovakalelo, nto leyo kufikelelwe yi ukukhuthazwa receptor-insulin.

Ngaphezu koko, glibenclamide uyakwazi ukwehlisa inyathelo zegazi ukuthintela ischemia engabalulekanga. Ichiza unalo inyathelo lothintelo nxamnye arrhythmias inhliziyo.

Njengoko imiswe kakuhle, ichiza ngaloo Ukunciphisa ubungozi bezinto iingxaki seswekile (type 2), eziquka seswekile cardiomyopathy, nephropathy kunye retinopathy. Medicine "Mannino" yemiyalezo ichaza njengendlela yokunciphisa inqanaba yokufa izifo ezinxulumene ne seswekile.

Yayibubungqina eziphambili ezibangela ukusetyenziswa glibenclamide - seswekile yohlobo yesibini, xa unyango ukudla wabonisa isiphumo ayanelisi. Tablets "Manin" zingasetyenziswa njenge-arhente ezimeleyo unyango, kwaye njengenxenye yonyango indibaniselwano kunye namanye amayeza anti-seswekile.

Kufuneka kukhunjulwe ukuba ixesha amayeza kunye nedosi yexabiso emiselwe ugqirha ngokusekelwe kwindlela ngamnye kumguli. Ngelo lokuqala unyango wamisa ngeedosi ezincinane wolawulo iziyobisi. Emva koko, indlela nokulungisa isicelo, kunye ulungiso ekutyeni. Iinkcukacha umthamo kwirejimeni uchazwe imiyalelo ukusebenzisa iziyobisi.

Isibaluli nendlela ithamo ngumphakamo glucose.

glibenclamide Ukwamkela kunokubangela iziphumo ezingalindelekanga, yeyona ixhaphakileyo leyo hypoglycemia. Iimpawu alo ukubila ngequbuliso, lafa, intloko ebuhlungu, iingxaki zezivamvo, kunye nabanye.

Izimo ukuze zolawulo echiza hypersensitivity ukuya amacandelo ongenziwanga unyango zamabanga, ketoacidosis, ukuphazamiseka "Mannino" ye izintso wesibindi.

Akukho lwazi lwaneleyo ukusetyenziswa ichiza abantwana, ogama yobudala ingadluli kwiminyaka eli-18.

Musa ukusebenzisa amayeza ngexesha uncancisa kwaye ngexesha lokukhulelwa.

Ukugcina ichiza kufuneka kubushushu ongekho ngaphezu kwama-25 C. Xa iimeko yokugcina kwithala wobomi ichiza iminyaka emi-3.